Effects of targeted colonic symbiotic supplementation with Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine on mental wellbeing: An open-label pilot study
Global Translational Medicine · 06.03.2026 · 5 (2) · 025460086
DOI: 10.36922/gtm025460086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Translational Medicine, online erschienen am 06.03.2026. Verfasst von Heike tom Dieck und 3 weiteren Autor:innen.
Abstract (Originalsprache)
The gut–brain axis plays a pivotal role in mental health, with synbiotic supplements emerging as promising interventions for stress and anxiety management. This observational open-label pilot study aims to evaluate the effects of a symbiotic supplement containing Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine, delivered via a targeted colonic-release capsule, on stress, anxiety, and mental wellbeing. Conducted as a non-placebo-controlled real-world case study, the study recruited 100 adults with elevated perceived stress and followed them for over eight weeks. Validated self-reporting tools, including the Depression Anxiety Stress Scales-21 items (DASS-21), Perceived Stress Scale-10 items (PSS-10), Athens Insomnia Scale (AIS), Short Form Health Survey-12 items, and Gastrointestinal Symptom Rating Scale questionnaires, were used to assess outcomes. Statistical analyses, primarily using linear mixed models, indicated reductions in DASS-21, PSS-10, and AIS scores, along with self-reported improvements in gastrointestinal symptoms and mental well-being. These findings should be interpreted cautiously due to the exploratory, uncontrolled study design. Notably, DASS-21 total scores declined within one week, with reported benefits sustained at four and eight weeks. However, these rapid changes may partly reflect expectancy effects or regression to the mean. These observations provide valuable insights for further hypothesis generation, notably that the synbiotic supplement could support stress management and mental health by modulating the gut–brain axis. However, further placebo-controlled trials including measurement of relevant biomarkers are warranted to confirm these observations and explore underlying mechanisms.
Zitieren
APA
Dieck, H. T., Tomassi, D., Postrach, E., & Ehring, E. (2026). Effects of targeted colonic symbiotic supplementation with Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine on mental wellbeing: An open-label pilot study. Global Translational Medicine, 5(2), 025460086. https://doi.org/10.36922/gtm025460086
Vancouver
Dieck HT, Tomassi D, Postrach E, Ehring E. Effects of targeted colonic symbiotic supplementation with Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine on mental wellbeing: An open-label pilot study. Global Translational Medicine. 2026;5(2):025460086. doi:10.36922/gtm025460086
BibTeX
@article{Dieck2026,
author = {Dieck, Heike tom and Tomassi, Diego and Postrach, Elisa and Ehring, Ellen},
title = {Effects of targeted colonic symbiotic supplementation with Bacillus subtilis DSM 32315 and L-alanyl-L-glutamine on mental wellbeing: An open-label pilot study},
journal = {Global Translational Medicine},
year = {2026},
volume = {5},
number = {2},
pages = {025460086},
doi = {10.36922/gtm025460086}
}
EUVIMED